StreetInsider.com News Articles

Waldencast Acquisition Corp. (WALD) PT Raised to $3 at Canaccord

Tue, 02 Jun 2026 06:49:39 -0400

(Updated - June 2, 2026 6:49 AM EDT)

Canaccord analyst Susan Anderson raised the price target on Waldencast Acquisition Corp. (NASDAQ: WALD) to $3.00 (from $2.00) while maintaining a Buy rating.

The analyst commented: "On June 1 before the market open, Waldencast (WALD) announced they have entered into an agreement to sell its Obagi skin care and aesthetics business to Bridgepoint. The transaction is valued up to $460M and comprises $366M in cash, a $10M fixed vendor note, a $20M adjustable vendor note, and up to $64M in earnout payments based on revenue milestones. The cash component of the deal is more

Waldencast Acquisition Corp. (WALD) PT Raised to $3 at Canaccord

Tue, 02 Jun 2026 06:49:39 -0400

(Updated - June 2, 2026 6:49 AM EDT)

Canaccord analyst Susan Anderson raised the price target on Waldencast Acquisition Corp. (NASDAQ: WALD) to $3.00 (from $2.00) while maintaining a Buy rating.

Form 6-K Waldencast plc For: Jun 01

Mon, 01 Jun 2026 09:54:00 -0400

si-local-file:///var/storage/secattach/20260601/26580674.html

Form 6-K Waldencast plc For: Jun 01

Mon, 01 Jun 2026 09:54:00 -0400

si-local-file:///var/storage/secattach/20260601/26580674.html

Waldencast agrees to sell Obagi Medical to Bridgepoint for up to $460 million

Mon, 01 Jun 2026 06:59:21 -0400

Waldencast plc (NASDAQ: WALD) announced it entered into a definitive agreement to sell its Obagi Medical dermatological skincare business to Bridgepoint for up to $460 million. The transaction is expected to close in the third quarter of 2026, subject to regulatory approvals and customary closing conditions.

The sale includes 100% of the equity interests in Obagi Medical, a medical-grade skincare company founded in 1988. The purchase price consists of an enterprise value of up to $460 million, subject to adjustments for net financial indebtedness, working capital variations, and contingent future payments.

Waldencast founders Michel Brousset and Hind Sebti, along with selected management

Waldencast Announces Sale of Obagi Medical to Bridgepoint

Mon, 01 Jun 2026 06:59:00 -0400

LONDON, June 01, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or “the Company”) today announced that it has entered into a definitive agreement to sell its Obagi Medical dermatological skincare and aesthetics business (“Obagi Medical”) to Bridgepoint, one of the world's leading mid-market investors, in a transaction valued at up to $460 million, marking a significant step in Waldencast’s strategy to strengthen its balance sheet and focus on accelerating the global growth of Milk Makeup.

Founded in 1988, Obagi Medical (www.obagi.com) is a pioneer in medical-grade skincare. Rooted in advanced

Waldencast Announces Sale of Obagi Medical to Bridgepoint

Mon, 01 Jun 2026 06:59:00 -0400

Founded in 1988, Obagi Medical (www.obagi.com) is a pioneer in medical-grade skincare. Rooted in advanced

Obagi Medical presents clinical data at Nashville dermatology conference

Fri, 15 May 2026 08:15:02 -0400

Obagi Medical, a unit of Waldencast plc (NASDAQ: WALD), presented clinical data on two skincare products at the Music City Symposium for Cosmetic Advances & Laser Education meeting held May 13-17 in Nashville.

The company shared results from a 12-week study of its NU-GEN Cellular Renewal Serum and interim findings from the ALOHA Program evaluating its Saypha MagIQ hyaluronic acid dermal filler used with medical-grade skincare products.

The NU-GEN study examined the serum's effects on wrinkles, hyperpigmentation, radiance, texture, firmness, plumpness, and perceived skin age. According to the company, the formula addresses nine signs of skin aging and clinical testing showed it

Obagi Medical presents clinical data at Nashville dermatology conference

Fri, 15 May 2026 08:15:02 -0400

Obagi Medical Shares New Data on Recent Innovations at Music City Symposium for Cosmetic Advances & Laser Education (SCALE) Meeting